Last updated on February 2018

A Study to Evaluate the Pharmacokinetics Safety and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)


Brief description of study

To satisfy a postmarketing requirement, the sponsor has been requested to conduct a Phase 1/Phase 2 single-group clinical study to investigate the pharmacokinetics and preliminary safety and efficacy of omacetaxine following a fixed-dose administration to patients with CP or AP CML who have failed 2 or more tyrosine kinase inhibitor (TKI) therapies.

Clinical Study Identifier: NCT02078960

Contact Investigators or Research Sites near you

Start Over

Teva U.S. Medical Information

Teva Investigational Site 12550
Atlanta, GA United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12543
Indianapolis, IN United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12547
Buffalo, NY United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12546
Cincinnati, OH United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12544
Houston, TX United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 37048
Gent, Belgium
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 37047
Leuven, Belgium
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 35157
Pierre Benite Cedex, France
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87029
Busan, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87032
Busan, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87033
Daegu-si, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87028
Jeonju, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87026
Seoul, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87031
Seoul, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87034
Suwon, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87027
Ulsan, Korea, Republic of
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12545
Jacksonville, FL United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12549
Fairway, KS United States
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 12548
Montreal, Canada
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 35158
Grenoble, France
  Connect »

Teva U.S. Medical Information

Teva Investigational Site 87030
Gyeonggi-do, Korea, Republic of
  Connect »